Fei Yu
Medtronic Plc, USA
Posters & Accepted Abstracts: J Biosens Bioelectron
Diabetes Mellitus is one of the most prevalent metabolic disorders which affect over 300 millions of patients worldwide. Diabetes patients are prone to prolonged period of hyperglycemia or hypoglycemia. If uncontrolled, it can pose serious health complications and extremely large financial burden to the patients and healthcare system. In order to achieve best possible blood sugar control and diabetes management, it is crucial to continuously monitor the blood glucose in addition to the chronical biomarkers such as Hemoglobin A1c. Continuous Glucose Monitoring (CMG) devices has existed for over a decade and is now receiving increasingly more attention from patients and healthcare providers worldwide, thanks to the advancement of sensing technologies as well as communication infrastructures, which allows connected care more feasible than ever before. This presentation serves to provide a technological overview of the commercially available CGM products as well as some of the novel CGM systems undergoing clinical trials. The scope of this overview covers operation principles for each sensing mechanism and will provide a discussion of respective advantages and disadvantages for enzymatic vs. non enzymatic reactions, electrochemical vs. optical sensing and non invasive vs. subcutaneous vs. implantable approaches. The presentation will also comment on the technical challenges faced by today�s CGM systems and the future research directions.
Email: fei.yu@medtronic.come
Biosensors & Bioelectronics received 6207 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 